Introduction
============

*Candida albicans*is an important opportunistic yeast that can cause mucosal infections, such as thrush and oropharyngeal candidiasis (OPC) in AIDS patients, as well as systemic life-threatening infections in immunocompromised patients \[[@B1]\]. The use of potent antifungal agents is crucial for the management of these potentially fatal infections. Azole antifungal agents, such as fluconazole, are the treatment of choice for these infections \[[@B2]\].

However, the increased use of these antifungal agents, especially in HIV/AIDS patients receiving long-term therapy, has resulted in the emergence of azole-resistant isolates of *C. albicans*. Azole resistance mechanisms are different and may contribute to mutations in encoding gene *ERG11*. It is based on the spatial configuration alterations of the target enzyme 14a-demethylase (ERG11p) \[[@B3], [@B4]\]. Erg11p is a significant protein of the cytochrome P450 superfamily enzyme and has an important role in the ergosterol synthesis pathway of *C. albicans*. Ergosterol (ergosta-5,7,22-trien-3β-ol) is a kind of sterol found in the fungal cell membranes and play a major role in maintaining the integrity and function of *C. albicans* membrane \[[@B5]\].

Mutations in *ERG*11 result in changes in the ERG11p spatial construction and reduce the affinity between the protein and azole \[[@B6]\]. The aim of the present study was to determine the susceptibility pattern of *C. albicans* clinical isolates to fluconazole using microdilution method. This study was also targeted toward the detection of mutations that might be responsible for fluconazole resistance by the amplification and sequencing of *ERG*11 gene.

Materials and Methods
=====================

***Clinical Isolates***

This study was conducted on a total of 216 clinical isolates obtained from Tehran (n=67), Isfahan (n=37), and Mashhad (n=112) cities in Iran, from July 2016 to February 2018. All strains were sub-cultured on Sabouraud glucose agar (SGA; Difco, Detroit, MI, USA) and incubated at 37°C for 24-48 h.

***Molecular Identification***

***DNA Extraction***

Genomic DNA was extracted using the boiling method. Briefly, a bit of fresh colonies were suspended in 80 µL of distilled water and boiled for 20 min. They were then centrifuged for 5 min at 6,000 rpm. The resultant supernatant was used for polymerase chain reaction (PCR). Clinical isolates of Tehran and Isfahan were identified using the PCR-restriction fragment length polymorphism (PCR-RFLP) of the ITS1-5.8S-ITS2 regions as described previously \[[@B7], [@B8]\]. Furthermore, the identification of the clinical samples of Mashhad was performed through matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF or MT-MS) mass spectrometry (Bruker Daltonics, Bremen, Germany), which is a new method.

***In vitro antifungal susceptibility testing***

Minimum inhibitory concentration (MICs) was determined according to the clinical and laboratory standards institute M27-A3 and M27-S4 documents \[[@B9], [@B10]\]. Antifungal effect of fluconazole (Pfizer Central Research, Sandwich, United Kingdom) was evaluated on the clinical isolates of *C. albicans*. To this end, fluconazole was diluted in the RPMI-1640 medium (Sigma Chemical Co.), buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS; Sigma) with L-glutamine without bicarbonate.

A final concentration of 0.063-64 μg/ml was considered for fluconazole. The MIC results were read after 24 h of incubation at 35°C. These values were determined visually as the lowest concentration of drug that caused a significant (\>50%) reduction in the microorganism growth. According to the M27-S4 document, a fluconazole concentration of \> 8 was considered for the resistant isolates \[[@B10]\].

***Amplification of ERG11 gene and sequencing***

Three pairs of primers were used for the amplification of *ERG11* gene \[[@B6]\]. ERGSec1A (50-TTAGTGTTTTATTGGATTCCTTGGTT-30) and ERGSec1B (50-TCTCATTTCATCACCAAATAAAGATC-30) yielded an amplicon expanding from 295 to 777 bp of the *ERG11* gene. Furthermore, ERGSec2A (50-ACCAGAAATTACTATTTTCACTGCTTCA-30) and ERGSec2B (50-AAGTCAAATCATTCAAATCACCA CCT-30) yielded a product extending from 723-1204 bp of the *ERG11* gene. Finally, ERGSec3A (50-AGGTGGTGATTTGAATGATTTGACTT-30) and ERGSec3B (50-GAACTATAATCAGGGTCAGGCACTTT-30) provided an expected PCR product extending from 1179-1667 bp of the *ERG11* gene.

One susceptible isolate (No. 27) was used as the control strain. The PCR mixture included 2.5 μl of 10X reaction buffer, 0.5 ml of 30 pmol/ml of each primer, 0.5 ml of 10 mM dNTP, 0.25 ml of Taq polymerase (5U/ml), and 2 μl of extracted DNA in a final volume of 25 μl. The PCR products were purified by means of the ethanol purification method. The cycle sequencing reactions were performed in forward and reverse directions (Bioneer, Korea).

The sequencing products were aligned and analyzed in comparison with the nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from *C. albican*\[[@B11]\] and published *ERG*11 sequence in GenBank by Lai and Kirsch (accession number: X13296) using MEGA (version 7) and Gene Runner software.

Results
=======

Out of 216 strains, 100 (46.3%) species were identified as *C. albicans*. The majority of the patients (23%) were in the age group of 31-40 years. Most of the specimens were collected from vaginitis (30%), onychomycosis (26%), and bronchoalveolar lavage (BAL; 21%) cases. The study population had a male to female ratio of 31:69. The most frequent predisposing factors among the patients included pregnancy (29%), cancer (9%), and diabetes mellitus (9%). An MIC range of 0.125-16 μg/ml was obtained for fluconazole having the MIC50 and MIC90 values of 0.5 and 1 μg/ml, respectively.

[Table 1](#T1){ref-type="table"} summarizes the demographic and clinical data of the patients enrolled in the present study. Isolates number 3, 11, 15, 23, and 45 were resistant to fluconazole (MIC=16); therefore, they were applied for sequencing. However, isolate number 3 was contaminated with *Aspergillus* species and did not recover on SGA. Totally, 41 nucleotides changes were detected among the isolates. Out of 41 mutations, 4 mutations in codons caused changes in ERG11p ([Table 1](#T1){ref-type="table"}) \[[@B6], [@B12]-[@B17]\].

###### 

Characteristics of patients with candidiasis and nucleotide changes and mutations of *Candida albicans* *ERG11* gene and correlated changes in ERG11p among resistant isolates in the present study

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **No**                  **City**   **Age**   **Gender**   **Source of specimen**   **Risk factor**          **MIC (µg/ml)**   **Site of nucleotide (bp) mutation**   **Nucleic acid mutation**   **Amino acid substitution**   **Change in**\
                                                                                                                                                                                                                                 **ERG11p**
  ----------------------- ---------- --------- ------------ ------------------------ ------------------------ ----------------- -------------------------------------- --------------------------- ----------------------------- ----------------
  1                       Mashhad    80        F            BAL                      \-                       0.125             \-                                     \-                          \-                            \-

  2                       Mashhad    39        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  3                       Mashhad    55        M            BAL                      Hepatitis                16                \-                                     \-                          \-                            \-

  4                       Mashhad    39        F            Bladder Biopsy           \-                       0.25              \-                                     \-                          \-                            \-

  5                       Mashhad    65        M            BAL                      Lung Cancer              0.25              \-                                     \-                          \-                            \-

  6                       Mashhad    52        M            BAL                      \-                       0.125             \-                                     \-                          \-                            \-

  7                       Mashhad    42        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  8                       Mashhad    39        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  9                       Mashhad    28        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  10                      Mashhad    48        M            BAL                      \-                       0.125             \-                                     \-                          \-                            \-

  11                      Mashhad    28        F            Vaginitis                Pregnancy                16                462\                                   TTT→TTC\                    Phe→Phe\                      N/C\
                                                                                                                                558\                                   TCC→TCT\                    Ser→Ser\                      N/C\
                                                                                                                                696\                                   CAT→CAC\                    His→His\                      N/C\
                                                                                                                                805\                                   CTA→TTA\                    Leu→Leu\                      N/C\
                                                                                                                                1143                                   GTT→GTC                     Val→Val                       N/C

  12                      Mashhad    55        F            BAL                      Lung cancer              0.125             \-                                     \-                          \-                            \-

  13                      Mashhad    63        M            BAL                      Leukemia                 0.25              \-                                     \-                          \-                            \-

  14                      Mashhad    44        M            BAL                      Lung cancer              4                 \-                                     \-                          \-                            \-

  15                      Mashhad    45        M            Joint                    Rheumatic diseases       16                462\                                   TTT→TTC\                    Phe→Phe\                      N/C\
                                                                                                                                504\                                   AAA→AAG\                    Lys→Lys\                      N/C\
                                                                                                                                558\                                   TCC→TCT\                    Ser→Ser\                      N/C\
                                                                                                                                805\                                   CTA→TTA\                    Leu→Leu\                      N/C\
                                                                                                                                945\                                   GAA→GAC\                    Glu→Asp\                      E266D^12^\
                                                                                                                                1143\                                  GTT→GTC\                    Val→Val\                      N/C\
                                                                                                                                1167\                                  TTA→TTG\                    Leu→Leu\                      N/C\
                                                                                                                                1257\                                  CTC→CTT\                    Leu→Leu\                      N/C\
                                                                                                                                1350\                                  TAT→TAC\                    Tyr→Tyr\                      N/C\
                                                                                                                                1443\                                  GCC→GCT\                    Ala→Ala\                      N/C\
                                                                                                                                1449\                                  GCT→GCC\                    Ala→Ala\                      N/C\
                                                                                                                                1587\                                  TTA→TTG\                    Leu→Leu\                      N/C\
                                                                                                                                1609\                                  GTT→ATT\                    Val→Ile\                      V488I^12^\
                                                                                                                                1617                                   AAT→AAC                     Asn→Asn                       N/C

  16                      Mashhad    65        M            BAL                      Lung cancer              0.25              \-                                     \-                          \-                            \-

  17                      Mashhad    79        F            BAL                      \-                       0.25              \-                                     \-                          \-                            \-

  18                      Mashhad    45        F            BAL                      Lung cancer              0.25              \-                                     \-                          \-                            \-

  19                      Mashhad    29        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  20                      Mashhad    39        M            BAL                      Kidney transplantation   0.25              \-                                     \-                          \-                            \-

  21                      Mashhad    53        F            Urine                    Kidney transplantation   0.25              \-                                     \-                          \-                            \-

  22                      Mashhad    53        M            BAL                      \-                       0.125             \-                                     \-                          \-                            \-

  23                      Mashhad    74        F            BAL                      Lung Cancer              16                696\                                   CAT→CAC\                    His→His\                      N/C\
                                                                                                                                805\                                   CTA→TTA\                    Leu→Leu\                      N/C\
                                                                                                                                1143\                                  GTT→GTC\                    Val→Val\                      N/C\
                                                                                                                                1287\                                  TTT→TTC\                    Phe→Phe\                      N/C\
                                                                                                                                1350\                                  TAT→TAC\                    Tyr→Tyr\                      N/C\
                                                                                                                                1443\                                  GCC→GCT\                    Ala→Ala\                      N/C\
                                                                                                                                1449                                   GCT→GCC                     Ala→Ala                       N/C

  24                      Mashhad    70        F            Biopsy                   Diabetes mellitus        0.25              \-                                     \-                          \-                            \-

  25                      Mashhad    35        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  26                      Mashhad    45        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  27                      Mashhad    29        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  28                      Mashhad    44        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  29                      Mashhad    29        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  30                      Mashhad    35        F            Thrush                   Lupus                    0.25              \-                                     \-                          \-                            \-

  31                      Mashhad    40        M            BAL                      Rheumatic diseases       0.25              \-                                     \-                          \-                            \-

  32                      Mashhad    28        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  33                      Mashhad    33        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  34                      Mashhad    26        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  35                      Mashhad    21        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  36                      Mashhad    32        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  37                      Mashhad    22        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  38                      Mashhad    31        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  39                      Mashhad    43        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  40                      Mashhad    22        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  41                      Mashhad    24        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  **Table 1.**Continued                                                                                                                                                                                                          

  42                      Mashhad    29        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  43                      Mashhad    28        F            Vaginitis                Pregnancy                0.125             \-                                     \-                          \-                            \-

  44                      Mashhad    36        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  45                      Mashhad    28        F            Vaginitis                Pregnancy                16                462\                                   TTT→TTC\                    Phe→Phe\                      N/C\
                                                                                                                                504\                                   AAA→AAG\                    Lys→Lys\                      N/C\
                                                                                                                                558\                                   TCC→TCT\                    Ser→Ser\                      N/C\
                                                                                                                                696\                                   CAT→CAC\                    His→His\                      N/C\
                                                                                                                                805\                                   CTA→TTA\                    Leu→Leu\                      N/C\
                                                                                                                                945\                                   GAA→GAC\                    Glu→Asp\                      E266D^12^\
                                                                                                                                1143\                                  GTT→GTC\                    Val→Val\                      N/C\
                                                                                                                                1167\                                  TTA→TTG\                    Leu→Leu\                      N/C\
                                                                                                                                1257\                                  CTC→CTT\                    Leu→Leu\                      N/C\
                                                                                                                                1350\                                  TAT→TAC\                    Tyr→Tyr\                      N/C\
                                                                                                                                1443\                                  GCC→GCT\                    Ala→Ala\                      N/C\
                                                                                                                                1449\                                  GCT→GCC\                    Ala→Ala\                      N/C\
                                                                                                                                1587\                                  TTA→TTG\                    Leu→Leu\                      N/C\
                                                                                                                                1609\                                  GTT→ATT\                    Val→Ile\                      V488I^12^\
                                                                                                                                1617                                   AAT→AAC                     Asn→Asn                       N/C

  46                      Mashhad    44        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  47                      Mashhad    73        M            BAL                      Lung cancer              0.25              \-                                     \-                          \-                            \-

  48                      Mashhad    34        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  49                      Mashhad    26        F            Vaginitis                Pregnancy                0.5               \-                                     \-                          \-                            \-

  50                      Mashhad    32        F            Vaginitis                Pregnancy                0.25              \-                                     \-                          \-                            \-

  51                      Mashhad    64        M            Urine                    Kidney transplantation   0.5               \-                                     \-                          \-                            \-

  52                      Isfahan    24        M            Groin                    \-                       0.5               \-                                     \-                          \-                            \-

  53                      Isfahan    28        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  54                      Isfahan    37        F            Toenail                  \-                       0.25              \-                                     \-                          \-                            \-

  55                      Isfahan    16        F            Fingernail               Diabetes mellitus        0.25              \-                                     \-                          \-                            \-

  56                      Isfahan    35        M            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  57                      Isfahan    39        M            Skin                     \-                       2                 \-                                     \-                          \-                            \-

  58                      Isfahan    48        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  59                      Isfahan    69        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  60                      Isfahan    41        M            BAL                      \-                       0.5               \-                                     \-                          \-                            \-

  61                      Isfahan    39        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  62                      Isfahan    3         M            Thrush                   \-                       0.5               \-                                     \-                          \-                            \-

  63                      Isfahan    40        F            Vaginitis                \-                       0.5               \-                                     \-                          \-                            \-

  64                      Isfahan    29        F            Fingernail               Diabetes mellitus        1                 \-                                     \-                          \-                            \-

  65                      Isfahan    14        F            Groin                    \-                       2                 \-                                     \-                          \-                            \-

  66                      Isfahan    45        F            Fingernail               \-                       2                 \-                                     \-                          \-                            \-

  67                      Isfahan    56        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  68                      Isfahan    39        M            Blood                    Leukemia                 1                 \-                                     \-                          \-                            \-

  69                      Isfahan    19        M            Toenail                  \-                       0.5               \-                                     \-                          \-                            \-

  70                      Tehran     74        F            Groin                    Diabetes mellitus        0.25              \-                                     \-                          \-                            \-

  71                      Tehran     65        F            BAL                      \-                       0.5               \-                                     \-                          \-                            \-

  72                      Tehran     71        F            Groin                    \-                       0.5               \-                                     \-                          \-                            \-

  73                      Tehran     78        M            Sputum                   \-                       2                 \-                                     \-                          \-                            \-

  74                      Tehran     48        M            Lung Biopsy              \-                       0.5               \-                                     \-                          \-                            \-

  75                      Tehran     68        F            Toenail                  \-                       0.5               \-                                     \-                          \-                            \-

  76                      Tehran     52        F            BAL                      \-                       0.5               \-                                     \-                          \-                            \-

  77                      Tehran     39        F            Fingernail               Diabetes mellitus        0.5               \-                                     \-                          \-                            \-

  78                      Tehran     61        F            Fingernail               \-                       0.25              \-                                     \-                          \-                            \-

  79                      Tehran     40        F            Toenail                  \-                       0.5               \-                                     \-                          \-                            \-

  80                      Tehran     65        M            Toenail                  Diabetes mellitus        0.5               \-                                     \-                          \-                            \-

  81                      Tehran     70        M            Interdigitale            \-                       0.5               \-                                     \-                          \-                            \-

  82                      Tehran     28        F            Fingernail               \-                       0.25              \-                                     \-                          \-                            \-

  83                      Tehran     34        M            Toenail                  Diabetes mellitus        0.5               \-                                     \-                          \-                            \-

  84                      Tehran     19        F            Fingernail               \-                       1                 \-                                     \-                          \-                            \-

  85                      Tehran     48        F            Fingernail               \-                       0.5               \-                                     \-                          \-                            \-

  86                      Tehran     18        M            Cornea                   \-                       0.5               \-                                     \-                          \-                            \-

  87                      Tehran     77        F            BAL                      \-                       0.25              \-                                     \-                          \-                            \-

  88                      Tehran     61        M            Sputum                   \-                       0.5               \-                                     \-                          \-                            \-

  89                      Tehran     59        F            Fingernail               \-                       1                 \-                                     \-                          \-                            \-

  90                      Tehran     47        F            Fingernail               Diabetes mellitus        0.5               \-                                     \-                          \-                            \-

  91                      Tehran     62        F            Fingernail               \-                       0.25              \-                                     \-                          \-                            \-

  92                      Tehran     34        F            Groin                    Hyperhidrosis            0.25              \-                                     \-                          \-                            \-

  **Table 1.**Continued                                                                                                                                                                                                          

  93                      Tehran     46        F            Toenail                  \-                       0.25              \-                                     \-                          \-                            \-

  94                      Tehran     58        M            Fingernail               \-                       0.25              \-                                     \-                          \-                            \-

  95                      Tehran     70        F            Toenail                  \-                       0.5               \-                                     \-                          \-                            \-

  96                      Tehran     86        F            Groin                    \-                       0.25              \-                                     \-                          \-                            \-

  97                      Tehran     27        M            Esophagitis              \-                       0.25              \-                                     \-                          \-                            \-

  98                      Tehran     10        M            Thrush                   Diabetes mellitus        0.5               \-                                     \-                          \-                            \-

  99                      Tehran     65        F            BAL                      \-                       0.5               \-                                     \-                          \-                            \-

  100                     Tehran     58        M            Skin                     Hyperhidrosis            0.5               \-                                     \-                          \-                            \-
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BAL: Bronchoalveolar lavage, MIC: minimum inhibitory concentration, M: male, F: female, N/C: no change, aa: amino acid, Phe: phenylalanine, Ser: serine, His: histidine, Leu: leucine, Val: valine, Lys: lysine, Glu: glutamine, Asp: aspartic acid, Tyr: tyrosine, Ala: alanine, Ile: isoleucine, Asn: asparagine

Discussion
==========

Candidiasis is referred to both superficial and deep-tissue fungal infections often caused by *C. albicans*. Based on the epidemiological surveys performed in the Europe \[[@B18]\], United States \[[@B19]\], and the Middle East \[[@B20]\], the superficial types can affect the oral, oropharynx, esophagus, and vaginal mucosa. *Candida albicans* is the main cause of invasive *Candida* infections in the majority of obtained clinical specimens, accounting for 50-70% of the cases \[[@B21]\]. The treatments of *Candida* infections differ considerably and are based on the patients\' underlying disease and immune status, anatomic location of the infection, *Candida* species responsible for infection, predisposing factors, and, in some cases, the susceptibility of *Candida* species to antifungal agents \[[@B22], [@B23]\].

Nystatin, itraconazole, miconazole, voriconazole, echinocandins, flucytosine, and amphotericin B are the anti-*Candida* agents applied for the management of this infection. However, the most prevalently recommended antifungal used for the majority of *C. albicans* isolates is fluconazole, which is a member of the azole class \[[@B24]\]. Azoles inhibit 14-α-sterol demethylase encoded by *ERG11* gene, which is a significant enzyme involved in the biosynthesis of ergosterol (i.e., fungal-specific membrane sterol).

Some investigations have shown the ability of *Candida* species to expand high resistance to azole agents \[[@B25], [@B26]\]. Prior ﬂuconazole exposure has been shown to increase the risk of ﬂuconazole resistance in *Candida* species \[[@B26]\]. Increased resistance to fluconazole is caused by different factors, such as the change of the target enzyme to diminish drug binding, reduction of the toxic effects of the antifungal, enhancement of the amount of the target enzyme, prevention from the intracellular accumulation of the antifungal agent \[[@B27]\], raised expression of *ERG11* as a result of activating mutations in the gene encoding the zinc-cluster transcriptional regulator Upc2p \[[@B28]\], overexpression of drug efflux pumps \[[@B29]\], and inactivation of *ERG3* gene \[[@B30]\].

*Candida albicans* strains isolated from patients with candidemia have the lowest incidence of azole resistance (0-5%) \[[@B31], [@B32]\]. However, the incidence of fluconazole resistance among the *C. albicans* clinical isolates of OPC is higher and is associated with prior OPC infections and previous fluconazole treatment \[[@B33]\]. Out of the 100 *C. albicans* clinical isolates, 5 isolates were resistant to fluconazole (MIC=16 μg/ml). Interestingly, all resistant strains belonged to Mashhad.

Resistant isolates were obtained from BAL (n=2), vaginitis (n=2), and joint (n=1). One isolate (from BAL) did not grow after re-passaging on SGA; therefore, it was excluded from the study. Amino acid substitutions have been delineated in 61 parts of the ERG11p due to mutations in *ERG11* gene \[[@B6]\]. Erg11p mutations, such as D153E, E266D, D116E, K128T, K147R, E266Q, K287R, G129A, and G303D, do not cause fluconazole resistance \[[@B12]-[@B14], [@B34], [@B35]\]. However, ERG11p mutations, such as G464S, Y132H, S405F, R467K, T315A, and I471T, have been shown to cause resistance to azoles \[[@B34], [@B36]-[@B40]\].

The C-terminal and N-terminal of ERG11p are on the protein surface rather than on the active site; therefore, the 295-1667 bp part of *ERG11* gene was amplified to look for possible mutations. Biofilms, multidrug transporters in *Candida* species, multiple drug resistance gene *MDR1*, drug segregation within intracellular vacuoles, and also overexpression of *CDR1*and*CDR2* as *Candida*drug-resistant genes can significantly reduce the intracellular drug concentration \[[@B4], [@B41], [@B42]\].

Susceptibility to fluconazole in *C.* *albicans* isolates may reach to 95.8% \[[@B43], [@B44]\]. However, as indicated in a number of investigations, the fluconazole resistance of such clinical isolates might be as high as 35% \[[@B45], [@B46]\]. In the present study, the incidence rate of fluconazole resistance in *C. albicans* was 5%. This low rate may be related to the administration of an appropriate dosage of antifungal agents or completion of the therapeutic course.

In this study, two types of mutations, including E266D and V488I, were detected among the resistant isolates. E266D mutation was also reported previously; nonetheless, this mutation does not result in fluconazole resistance \[[@B12]\]. V488I (G1609A) mutation may not also lead to fluconazole resistance because V488 is located far from the active center of ERG11p \[[@B47]\]. Khademi et al. found four resistant *C. albicans* strains among patients in Guilan, Iran. Missense mutations, such as C470G, K291N, and Q474R, were detected in all resistant isolates.

Similar to our results, Teymori et al. \[[@B48]\] detected 5 (5.1%) resistant *C. albicans* isolates (MIC≥64 μg/ml) out of 97 clinical samples. They revealed that *ERG*11 gene in the five fluconazole-resistant *C. albicans* isolates was up-regulated 4.15-5.84 folds, compared to the control strain. Eftekhari et al. \[[@B49]\] isolated 4 resistant *C. albicans* out of 40 strains and screened *ERG*11 gene mutations by PCR sequencing. Their isolated strains had D116E and V456G polymorphisms.

In another study carried out during April 2015-April 2016, Alizadeh et al. \[[@B50]\] isolated 28 strains of *C. albicans* from muco-cutaneous candidiasis among immunocompromised patients in Omidiyeh, Khuzestan, Iran. In the mentioned study, all isolates were resistant to fluconazole. They evaluated *ERG* gene expression by semi-quantitative reverse transcriptase-(RT) PCR. In line with the results of the present study, they showed no significant changes in fluconazole-resistant isolates in comparison with untreated controls and *ERG*11 reference sequence.

In 2017, Balabandi et al. \[[@B51]\] detected two missense mutations (i.e., D116E and E266D) in *ERG*11 gene among 20 resistant *C. albicans* in Rasht, Iran. Furthermore, Peron et al. \[[@B52]\] found two fluconazole-resistant *C. albicans* isolates from oral cavity (MIC=8 μg/ml) and esophageal cavity (MIC=64 μg/ml). They found six mutations encoding distinct amino acid substitutions (i.e., E116D, T128K, E266D, A298V, G448V, and G464S) that were previously reported to be associated with fluconazole resistance.

Moron and Cabrera \[[@B53]\] isolated 26 clinical strains from two tertiary hospitals in Metro Manila, Philippines, during November 2016 to January 2017. Out of 26 *C. albicans*, a high percentage of the isolates (73.08%) showed resistance to fluconazole. They detected the presence of point mutations T462C, A369C, and C558T. Mutations A369C and T462C have been also identified as possible factors associated with resistance to azole agents \[[@B54]\].

Conclusion
==========

In accordance with many investigations in this field, our results demonstrated that the majority of *C.* *albicans* isolates were susceptible to fluconazole. Since the main mechanism of azole resistance is the mutation occurring through the *ERG11* gene in *C. albicans*, this gene was selected for analysis in the present study. Our analysis resulted in the detection of 41 mutations in codons, only 4 of which caused changes in ERG11p. Nonetheless, these mutations (i.e., E266D and V488I) cannot lead to fluconazole resistance. Resistance among these isolates could be due to other mechanisms, such as the prevention of the intracellular accumulation of the antifungal agent and alteration of the target enzyme to diminish drug binding.
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